TRCT
PLYX

Tower Research Capital (TRC)’s Polaryx Therapeutics Inc PLYX Stock Holding History

Tower Research Capital (TRC)’s Portfolio PLYX Stock Details PLYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.99K Buy
3,002
+1,221
+69% +$4.79K ﹤0.01% 4102
2026
Q1 		$13.5K Buy
+1,781
New +$11.5K ﹤0.01% 3741

Other funds holding PLYX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Tower Research Capital (TRC)'s PLYX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Polaryx Therapeutics Inc (PLYX) stake by 69% in Q2 2026, buying an estimated $4.79K and bringing the position to 3,002 shares worth $7.99K. The position accounts for ﹤0.01% of the portfolio, ranked #4102.

Tower Research Capital (TRC) first reported a position in PLYX in Q1 2026 and has held it in 2 quarters since. The position peaked at $13.5K in Q1 2026. 13 funds tracked by Wall St. Rank hold PLYX as of Q2 2026.

  • Tower Research Capital (TRC) held 3,002 shares of Polaryx Therapeutics Inc worth $7.99K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,221 Polaryx Therapeutics Inc shares in Q2 2026, an estimated $4.79K.
  • Polaryx Therapeutics Inc made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4102 holding.
  • Tower Research Capital (TRC) first reported a position in Polaryx Therapeutics Inc in Q1 2026 and has held it in 2 quarters since.
  • Tower Research Capital (TRC)'s Polaryx Therapeutics Inc position peaked at $13.5K in Q1 2026.
  • 13 funds tracked by Wall St. Rank held Polaryx Therapeutics Inc as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.